As Sun Sets On Copaxone, Teva Looks To New BD Horizons
This article was originally published in The Pink Sheet Daily
Acting CEO Eyal Desheh said the company will be more open-minded about business development during the company’s fourth quarter financial call Feb. 6. Investors will have to wait to hear from incoming CEO Erez Vigodman for any new strategy to be articulated, however.
You may also be interested in...
Sanofi shows solid growth in emerging markets in the fourth quarter, including an impressive 35.1% gain in China. Teva in transition offers scant detail on emerging markets, but hints larger deals possible in 2014.
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.